Theresa Wampler Muskardin1, Priyanka Vashisht2, Jessica M Dorschner1, Mark A Jensen1, Beverly S Chrabot3, Marlena Kern4, Jeffrey R Curtis5, Maria I Danila5, Stacey S Cofield5, Nancy Shadick6, Peter A Nigrovic6, E William St Clair7, Clifton O Bingham8, Richard Furie9, William Robinson10, Mark Genovese10, Christopher C Striebich11, James R O'Dell2, Geoffrey M Thiele2, Larry W Moreland12, Marc Levesque12, S Louis Bridges5, Peter K Gregersen4, Timothy B Niewold1. 1. Division of Rheumatology, Mayo Clinic, Rochester, Minnesota, USA. 2. Division of Rheumatology, University of Nebraska Medical Center, Omaha, USA. 3. Gwen Knapp Center for Lupus and Immunology Research, University of Chicago, Chicago, Illinois, USA. 4. Center for Genomics and Human Genetics, Feinstein Institute Medical Research, North Shore LIJ Health System, New York, New York, USA. 5. Division of Clinical Immunology and Rheumatology, University of Alabama, Birmingham, Alabama, USA. 6. Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, Massachusetts, USA. 7. Division of Rheumatology and Immunology, Duke University, Durham, USA. 8. Divisions of Rheumatology and Allergy, Johns Hopkins University, Baltimore, USA. 9. Division of Rheumatology and Allergy-Clinical Immunology, North Shore-LIJ Health System, Lake success, New York, USA. 10. Division of Immunology and Rheumatology, Stanford University, Stanford, California, USA. 11. Division of Rheumatology, University of Colorado Denver, Denver, USA. 12. Division of Rheumatology, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.
Abstract
OBJECTIVE: Studies suggest that circulating type I interferon (IFN) may predict response to biological agents in rheumatoid arthritis (RA). Prediction of response prior to initiating therapy would represent a major advancement. METHODS: We studied sera from a test set of 32 patients with RA from the Auto-immune Biomarkers Collaborative Network Consortium and a validation set of 92 patients with RA from the Treatment Efficacy and Toxicity in Rheumatoid Arthritis Database and Repository registry. The test set included those with good response or no response to tumour necrosis factor (TNF) inhibitors at 14 weeks by European League Against Rheumatism criteria. The validation set included subjects with good, moderate or no response at 12 weeks. Total serum type I IFN activity, IFN-α and IFN-β activity were measured using a functional reporter cell assay. RESULTS: In the test set, an increased ratio of IFN-β to IFN-α (IFN-β/α activity ratio) in pretreatment serum associated with lack of response to TNF inhibition (p=0.013). Anti-cyclic citrullinated peptide antibody titre and class of TNF inhibitor did not influence this relationship. A receiver-operator curve supported a ratio of 1.3 as the optimal cut-off. In the validation set, subjects with an IFN-β/α activity ratio >1.3 were significantly more likely to have non-response than good response (OR=6.67, p=0.018). The test had 77% specificity and 45% sensitivity for prediction of non-response compared with moderate or good response. Meta-analysis of test and validation sets confirmed strong predictive capacity of IFN-β/α activity ratio (p=0.005). CONCLUSIONS: Increased pretreatment serum IFN-β/α ratio strongly associated with non-response to TNF inhibition. This study supports further investigation of serum type I IFN in predicting outcome of TNF inhibition in RA. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/
OBJECTIVE: Studies suggest that circulating type I interferon (IFN) may predict response to biological agents in rheumatoid arthritis (RA). Prediction of response prior to initiating therapy would represent a major advancement. METHODS: We studied sera from a test set of 32 patients with RA from the Auto-immune Biomarkers Collaborative Network Consortium and a validation set of 92 patients with RA from the Treatment Efficacy and Toxicity in Rheumatoid Arthritis Database and Repository registry. The test set included those with good response or no response to tumour necrosis factor (TNF) inhibitors at 14 weeks by European League Against Rheumatism criteria. The validation set included subjects with good, moderate or no response at 12 weeks. Total serum type I IFN activity, IFN-α and IFN-β activity were measured using a functional reporter cell assay. RESULTS: In the test set, an increased ratio of IFN-β to IFN-α (IFN-β/α activity ratio) in pretreatment serum associated with lack of response to TNF inhibition (p=0.013). Anti-cyclic citrullinated peptide antibody titre and class of TNF inhibitor did not influence this relationship. A receiver-operator curve supported a ratio of 1.3 as the optimal cut-off. In the validation set, subjects with an IFN-β/α activity ratio >1.3 were significantly more likely to have non-response than good response (OR=6.67, p=0.018). The test had 77% specificity and 45% sensitivity for prediction of non-response compared with moderate or good response. Meta-analysis of test and validation sets confirmed strong predictive capacity of IFN-β/α activity ratio (p=0.005). CONCLUSIONS: Increased pretreatment serum IFN-β/α ratio strongly associated with non-response to TNF inhibition. This study supports further investigation of serum type I IFN in predicting outcome of TNF inhibition in RA. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/
Authors: Corinna E Weckerle; Beverly S Franek; Jennifer A Kelly; Marissa Kumabe; Rachel A Mikolaitis; Stephanie L Green; Tammy O Utset; Meenakshi Jolly; Judith A James; John B Harley; Timothy B Niewold Journal: Arthritis Rheum Date: 2011-04
Authors: Clio P Mavragani; Timothy B Niewold; Niki M Moutsopoulos; Stanley R Pillemer; Sharon M Wahl; Mary K Crow Journal: Arthritis Rheum Date: 2007-12
Authors: Jeffrey R Curtis; Theresa McVie; Ted R Mikuls; Richard J Reynolds; Iris Navarro-Millán; James O'Dell; Larry W Moreland; S Louis Bridges; Veena K Ranganath; Stacey S Cofield Journal: J Rheumatol Date: 2013-04-15 Impact factor: 4.666
Authors: Gunther Hartmann; Veit Hornung; Sarah Kim; Vera Kaiser; Esther Beier; Matthias Bechheim; Margit Guenthner-Biller; Andrea Ablasser; Michael Berger; Stefan Endres Journal: Eur J Immunol Date: 2014-01-16 Impact factor: 5.532
Authors: Hennie G Raterman; Saskia Vosslamber; Sander de Ridder; Michael T Nurmohamed; Willem F Lems; Maarten Boers; Mark van de Wiel; Ben A C Dijkmans; Cornelis L Verweij; Alexandre E Voskuyl Journal: Arthritis Res Ther Date: 2012-04-27 Impact factor: 5.156
Authors: Sarah L Jongbloed; M Cristina Lebre; Alasdair R Fraser; J Alastair Gracie; Roger D Sturrock; Paul P Tak; Iain B McInnes Journal: Arthritis Res Ther Date: 2006 Impact factor: 5.156
Authors: Faruk Sheikh; Harold Dickensheets; Ana M Gamero; Stefanie N Vogel; Raymond P Donnelly Journal: J Leukoc Biol Date: 2014-07-14 Impact factor: 4.962
Authors: Divya N V Challa; Zoran Kvrgic; Cynthia S Crowson; Eric L Matteson; Thomas G Mason; Clement J Michet; Daniel E Schaffer; Kerry A Wright; John M Davis Journal: Arthritis Care Res (Hoboken) Date: 2019-12-10 Impact factor: 4.794
Authors: Jonas Bystrom; Felix I Clanchy; Taher E Taher; Mohammed M Al-Bogami; Hawzheen A Muhammad; Saba Alzabin; Pamela Mangat; Ali S Jawad; Richard O Williams; Rizgar A Mageed Journal: Clin Rev Allergy Immunol Date: 2017-10 Impact factor: 8.667
Authors: Theresa L Wampler Muskardin; Wei Fan; Zhongbo Jin; Mark A Jensen; Jessica M Dorschner; Yogita Ghodke-Puranik; Betty Dicke; Danielle Vsetecka; Kerry Wright; Thomas Mason; Scott Persellin; Clement J Michet; John M Davis; Eric Matteson; Timothy B Niewold Journal: Front Immunol Date: 2020-07-16 Impact factor: 7.561
Authors: Javier Rodríguez-Carrio; Patricia López; Mercedes Alperi-López; Luis Caminal-Montero; Francisco J Ballina-García; Ana Suárez Journal: Front Immunol Date: 2019-01-07 Impact factor: 7.561